Guest: Dr. Timothy Craig
Presenter: Neal Howard
Guest Bio: Dr. Timothy Craig is a Professor of Medicine and Pediatrics at Penn State University. He trained in the US Navy after which he started his academic career at the University of Iowa and then transferred to Penn State to start an Allergy and Immunology Program. He is a Distinguished Educator, Program Director, Section Chief and a Fellow of the AAAAI, ACP, ACAAI and ACOI. Dr Craig is the director of the Alpha-1-Deficiency Center at Penn State University. He is the recipient of multiple teaching awards, has published over 250 manuscripts and has delivered over 350 invited lectures. Lastly, he is proud to be a Vietnam Education Foundation Scholar.
Segment overview: Dr. Timothy Craig, DO, Professor of Medicine and Pediatrics, Pennsylvania State University Medical School, discusses the new FDA approved CSL Behring’s HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [human]), the only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema (HAE) attacks in adolescent and adult patients.
Transcript – TBU